Power Corporation of Canada banner

Intrinsic Value

The intrinsic value of Power Corporation of Canada (PCR) under the Base Case is 53.69 EUR per share. Compared with the current market price of 59.66 EUR, the stock appears Overvalued by 10% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

PCR Intrinsic Value
€53.69
Overvaluation 10%
Intrinsic Value
Price €59.66
Alert me when PCR is below its intrinsic value
Today €42.95 · 28.0% below the current price

PCR is more expensive than usual. It was this expensive or more expensive on just 11% of days in the past 5 years.

Alternatives to PCR

Fundamental Analysis

What Power Corporation of Canada Does

Insurance Financials

Power Corporation of Canada is a holding company, not a single operating brand. It owns and controls businesses in financial services, mainly through stakes in insurance, wealth management, and asset management companies. Its key businesses sell life insurance, retirement and investment products, and financial advice to individuals, families, employers, and institutions.

Headquarters
Canada CA
Employees
30 000
IPO date
Jan 1, 1985
Read the full company overview
View Company Overview

Power Corporation of Canada has no economic moat

No Moat Narrow Wide

Customers can find similar insurance and investment products from established insurers, banks and fund managers, limiting Power Corporation’s ability to charge more or keep costs beyond rivals’ reach. Its holdings in Great-West Lifeco and IGM Financial provide broad distribution, but do not make those alternatives unavailable.

Read the full moat analysis
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue PCR Research

Decided on Power Corporation of Canada? Get an email when PCR reaches the price you’d buy at. Free with an account.

Other Power Corporation of Canada listings

What is the Intrinsic Value of one PCR stock?

The intrinsic value for Power Corporation of Canada (PCR) under the Base Case is 53.69 EUR.

Is PCR stock undervalued or overvalued?

Compared with the current market price of 59.66 EUR, the stock appears Overvalued by 10% .

How reliable are our estimates? See how past valuations played out
Back to Top